On May 15, 2026, ProKidney Corp. announced its financial results for Q1 2026, mentioning a significant improvement in kidney function as seen in a clinical study, with a 4.6 mL/min/1.73m² enhancement in eGFR slope from treatments. The company is preparing for pivotal data results in mid-2026 for its Phase 3 trial.